昊海生物科技(06826)发布公告，关于第二期A股股份回购实施结果，截至2025年8月14日，公司已完成 本期回购。公司通过上海证券交易所系统以集中竞价交易方式已累计回购A股股份183.24万股，占公司 总股本比例为0.79%，回购成交的最高价为63.58元/股，最低价为49.25元/股，回购均价为56.70元/股， 支付的资金总额为人民币1.039亿元(不含印花税、交易佣金等费用)。 ...

智通财经APP讯，昊海生物科技(06826)发布公告，关于第二期A股股份回购实施结果，截至2025年8月 14日，公司已完成本期回购。公司通过上海证券交易所系统以集中竞价交易方式已累计回购A股股份 183.24万股，占公司总股本比例为0.79%，回购成交的最高价为63.58元/股，最低价为49.25元/股，回购 均价为56.70元/股，支付的资金总额为人民币1.039亿元(不含印花税、交易佣金等费用)。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 海外監管公告 本公告乃由上海昊海生物科技股份有限公司（「本公司」）根據《香港聯合交易所有 限公司證券上市規則》第13.10B條的規定刊發。 茲載列本公司在上海證券交易所網站刊登之《上海昊海生物科技股份有限公司關 於第二期A股股份回購實施結果公告》，僅供參考。 承董事會命 上海昊海生物科技股份有限公司 主席 侯永泰 中國上海，2025年8月15日 於本公告日期，本公司之執行董事為侯永泰博士、吳劍英先生、陳奕奕女士及唐 敏捷先生；本公司之非執行董事為游捷女士、黃明先生及魏長征先生；及本公司 之獨立非執行董事為沈紅波先生、姜志宏先生、蘇治先生及楊玉社先生。 一、 回购审批情况和回购方案内容 上海昊海生物科技股份有限公司 ...

Group 1 - The core business of Haohai Biological Technology is primarily in the pharmaceutical manufacturing sector, accounting for 99.83% of its revenue, while other businesses contribute only 0.17% [1] Group 2 - As of August 15, 2025, Haohai Biological Technology has completed its share repurchase program, acquiring approximately 1.83 million A-shares, which represents 0.79% of the total share capital of about 233 million shares [3] - The highest price for the repurchased shares was 63.58 CNY per share, the lowest was 49.25 CNY per share, and the average repurchase price was 56.7 CNY per share, with a total expenditure of approximately 104 million CNY [3]

证券代码：688366 证券简称：昊海生科 公告编号：2025-037 上海昊海生物科技股份有限公司 关于第二期 A 股股份回购实施结果公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/8/17 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 月 2024 8 8 | 16 | 日~2025 | 年 | 月 | 日 15 | | 预计回购金额 | 10,000.00万元~20,000.00万元 | | | | | | | 回购价格上限 | 88.72元/股（调整前为 89.71 | | | | | 元/股） | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | □用于转换公司可转债 | | | | | | | | □为维护公司价值及股东权益 | | | | | | | 实际回购股数 | 1,832,421股 | | | | | ...

格隆汇8月15日丨昊海生科(688366.SH)公布，截至2025年8月14日，公司已完成本期回购。公司通过上 海证券交易所系统以集中竞价交易方式已累计回购A股股份183.24万股，占公司总股本的比例为 0.79%，回购成交的最高价为63.58元/股，最低价为49.25元/股，回购均价为56.70元/股，支付的资金总 额为人民币1.04亿元（不含印花税、交易佣金等费用）。 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Haohai Biological Technology Co., Ltd. in the medical device industry [1][2] - As of August 15, Haohai's stock closed at 55.18 yuan, with a rolling PE ratio of 31.06 times and a total market capitalization of 12.834 billion yuan [1] - The average PE ratio for the medical device industry is 56.58 times, with a median of 39.97 times, placing Haohai at the 60th position in the industry ranking [1][2] Group 2 - As of February 29, 2020, Haohai had 7,605 shareholders, an increase of 918 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The company's main business includes the research, production, and sales of medical devices and pharmaceuticals, with key products such as ophthalmic viscoelastic devices, artificial lenses, and hyaluronic acid [1] - In the latest quarterly report for Q1 2025, Haohai reported revenue of 619 million yuan, a year-on-year decrease of 4.25%, and a net profit of 90.31 million yuan, down 7.41%, with a gross profit margin of 69.52% [1]

上海昊海生物科技股份有限公司的主营业务是医疗器械和药品研发、生产和销售。公司的主要产品是眼 科粘弹剂、人工晶状体、视光材料、视光终端产品、玻尿酸、人表皮生长因子、射频及激光设备、玻璃 酸钠注射液、医用几丁糖（关节腔注射用）、医用几丁糖（防粘连用）、医用透明质酸钠凝胶、胶原蛋 白海绵。 最新一期业绩显示，2025年一季报，公司实现营业收入6.19亿元，同比-4.25%；净利润9031.21万元，同 比-7.41%，销售毛利率69.52%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13昊海生科30.7530.222.24127.06亿行业平均 55.7651.784.91117.92亿行业中值39.1439.592.8556.79亿1九安医疗11.1811.310.88188.72亿2英科医疗 14.7815.931.32233.49亿3山东药玻16.1716.211.86152.90亿4新华医疗16.3115.111.33104.53亿5振德医疗 17.0416.061.0861.87亿6奥美医疗17.0716.731.7561.68亿7九强生物17.6516.412.1687.42亿8康德莱 1 ...

Summary of Key Points Core Viewpoint - The investment and financing landscape of the medical beauty injection materials industry in China is relatively mature, with a significant number of investment events and a focus on scientific research and technology services. Group 1: Financing Status - As of June 2025, there have been 39 investment events in the medical beauty injection materials industry, indicating a mature investment environment [2][4]. - The majority of financing events are concentrated in Shandong and Jiangsu provinces, with Shandong having 8 events and Jiangsu 7 events [4]. Group 2: External Investment Layout - Representative companies in the medical beauty injection materials industry have engaged in numerous external investment events, primarily focusing on scientific research and technology services, which account for approximately 58% of their investments [14][13]. - Other sectors of investment include manufacturing (18%) and wholesale and retail (8%) [14]. Group 3: Mergers and Acquisitions - The level of mergers and acquisitions in the medical beauty injection materials industry is relatively low, with notable participation from real estate companies. For instance, Lushang Development acquired 100% of Shandong Furuida Pharmaceutical Group in 2018 to enter the medical beauty sector [16].

Core Insights - The coronary artery stent market in China is projected to reach approximately $7.0 billion by 2024, with a year-on-year growth of 6.4% [5][6]. Market Overview - In 2023, 8.368 million patients were hospitalized for coronary heart disease, with 1.901 million undergoing PCI (Percutaneous Coronary Intervention), where stent placement accounted for 81.2% of these procedures [3][6]. Product Structure - Drug-eluting stents (DES) dominate the market, expected to account for 69% of market revenue in 2024. The increasing prevalence of hypertension and diabetes due to aging populations and lifestyle changes is driving demand for DES [7][6]. Development Trends - **Material Innovation**: New alloy materials such as platinum-chromium and nickel-titanium are increasingly used due to their superior mechanical properties and biocompatibility. Biodegradable materials like polylactic acid and polycaprolactone are also being adopted to mitigate long-term foreign body reaction risks [11]. - **Functional Innovation**: Improvements in drug carriers for drug-eluting stents enhance drug release efficiency, reducing the risk of late thrombosis. Smart stents integrating sensors can monitor physiological parameters in real-time and adjust drug release accordingly [11].